Antidepressants and survival in glioma-A registry-based retrospective cohort study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Antidepressant use is common in malignant glioma patients and is linked to poorer survival rates for both selective serotonin reuptake inhibitors (SSRIs) and non-SSRIs. Further research is needed to understand this association between antidepressants and glioma survival.
Area Of Science
- Neuro-oncology
- Clinical pharmacology
- Epidemiology
Background
- Malignant glioma patients frequently experience depression and are treated with antidepressants.
- The impact of antidepressant medication on glioma progression and patient survival remains unclear.
- Understanding this relationship is crucial for optimizing patient care and treatment strategies.
Purpose Of The Study
- To investigate the association between antidepressant medication use and survival outcomes in patients diagnosed with malignant glioma.
- To determine if different classes of antidepressants (SSRIs vs. non-SSRIs) have varying effects on glioma patient survival.
Main Methods
- A registry-based cohort study was conducted using data from the RISK North database in Sweden.
- Included were 1231 patients with malignant glioma (WHO grades 2, 3, and 4) who had undergone surgery.
- 6400 matched controls without glioma were used for comparison.
Main Results
- Antidepressant use was significantly more common in glioma patients (27%) than in controls (16%).
- Treatment with antidepressants post-surgery was associated with significantly poorer survival in glioma patients.
- Both SSRIs and non-SSRIs showed a negative association with survival, with Hazard Ratios ranging from 3.26 to 7.71 depending on glioma grade and antidepressant type.
Conclusions
- The study demonstrates a negative association between antidepressant medication and survival in patients with malignant glioma.
- These findings suggest antidepressants may negatively impact glioma survival, but further research is required to establish causality.
- Clarifying the causal relationship is essential for informing clinical decisions regarding antidepressant use in glioma patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...